New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms

Diabetes Research and Clinical Practice

Volumn 93, Issue SUPPL. 1, 2011, Pages S9-

  Schäfer, Silke A ^a   Machicao, Fausto ^a   Fritsche, Andreas ^a   Häring, Hans Ulrich ^a   Kantartzis, Konstantinos ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Genome wide association studies; Incretins; Insulin secretion; Insulin sensitivity; MTNR1B; TCF7L2; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TRANSPORTER; INCRETIN; INSULIN; PROINSULIN;

ARTICLE; FORKHEAD BOX O1 GENE; GENE; GENE ACTIVITY; GENE INTERACTION; GENE THERAPY; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMATOPOIETICALLY EXPRESSED HOMEOBOX GENE; HORMONAL REGULATION; HORMONE SENSITIVITY; HUMAN; INSULIN RELEASE; LIFESTYLE; MELATONIN RECEPTOR 1B GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENOMICS; POTASSIUM VOLTAGE GATE CHANNEL KQT LIKE SUBFAMILY MEMBER 1 GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION FACTOR 7 LIKE 2 GENE; WOLFRAM SYNDROME 1 GENE;

EID: 84860417551     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/S0168-8227(11)70008-0     Document Type: Article

References (240)

1. Zimmet P, Alberti KG, Shaw J Global and societal implications of the diabetes epidemic. Nature 2001, 414(6865):782-787.
2. Wild S, Roglic G, Green A, Sicree R, King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102-110.
4. Stumvoll M, Goldstein BJ, van Haeften TW Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365(9467):1333-1346.
5. Wajchenberg BL beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28(2):187-218.
6. Pierce M, Keen H, Bradley C Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 1995, 12(1):1-6.
7. Gloyn AL, McCarthy MI The genetics of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2001, 15(3):293-308.
8. Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes 2007, 115(10):634-640.
9. Elbein SC The genetics of human noninsulin-dependent (type 2) diabetes mellitus. J Nutr 1997, 127(9):1891S-1896S.
10. Zimmet PZ, McCarty DJ, de Court The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications 1997, 11(2):60-68.
11. Knowler WC, Bennett PH, Hamman RF, Miller M Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978, 108(6):497-505.
12. Vaxillaire M, Froguel P Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev 2008, 29(3):254-256.
13. Collins FS, Guyer MS, Charkravarti A Variations on a theme: cataloging human DNA sequence variation. Science 1997, 278(5343):1580-1581.
14. Staiger H, Machicao F, Fritsche A, Haring HU Pathomechanisms of type 2 diabetes genes. Endocr Rev 2009, 30(6):557-585.
15. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 2007, 445(7130):881-885.
16. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000, 271(1):212-216.
17. Parikh H, Groop L Candidate genes for type 2 diabetes. Rev Endocr Metab Disord 2004, 5(2):151-176.
18. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003, 33(2):177-182.
19. Stumvoll M, Haring H The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes 2002, 51(8):2341-2347.
20. Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes 2003, 52(2):573-577.
21. Florez JC, Burtt N, de Bakker PI, Almgren P, Tuomi T, Holmkvist J, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004, 53(5):1360-1368.
22. Vaxillaire M, Veslot J, Dina C, Proenca C, Cauchi S, Charpentier G, et al. Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. Diabetes 2008, 57(1):244-245.
23. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26(2):163-175.
24. Evans JC, Frayling TM, Cassell PG, Saker PJ, Hitman GA, Walker M, et al. Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001, 69(3):544-552.
25. Tsuchiya T, Schwarz PE, Bosque-Plata LD, Geoffrey HM, Dina C, Froguel P, et al. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol Genet Metab 2006, 89(1-2):174-184.
26. Jensen DP, Urhammer SA, Eiberg H, Borch-Johnsen K, Jorgensen T, Hansen T, et al. Variation in CAPN10 in relation to type 2 diabetes, obesity and quantitative metabolic traits: studies in 6018 whites. Mol Genet Metab 2006, 89(4):360-367.
27. Bacci S, Ludovico O, Prudente S, Zhang YY, Di Paola R, Mangiacotti D, et al. The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. Diabetes 2005, 54(10):3021-3025.
28. McAteer JB, Prudente S, Bacci S, Lyon HN, Hirschhorn JN, Trischitta V, et al. The ENPP1 K121Q polymorphism is associated with type 2 diabetes in European populations: evidence from an updated meta-analysis in 42,042 subjects. Diabetes 2008, 57(4):1125-1130.
29. Bouhaha R, Meyre D, Kamoun HA, Ennafaa H, Vaillant E, Sassi R, et al. Effect of ENPP1/PC-1-K121Q and PPARgamma-Pro12Ala polymorphisms on the genetic susceptibility to T2D in the Tunisian population. Diabetes Res Clin Pract 2008, 81(3):278-283.
30. Scott LJ, Mohlke KL, Bonnycastle LL, Wilier CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316(5829):1341-1345.
31. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316(5829):1331-1336.
32. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007, 316(5829):1336-1341.
33. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008, 359(21):2220-2232.
34. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008, 40(5):638-645.
35. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002, 51(2):536-540.
36. Vasseur F, Helbecque N, Lobbens S, Vasseur-Delannoy V, Dina C, Clement K, et al. Hypoadiponectinaemia and high risk of type 2 diabetes are associated with adiponectin-encoding (ACDC) gene promoter variants in morbid obesity: evidence for a role of ACDC in diabesity. Diabetologia 2005, 48(5):892-899.
37. Gable DR, Matin J, Whittall R, Cakmak H, Li KW, Cooper J, et al. Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects. Ann Hum Genet 2007, 71(Pt4):453-466.
38. Bostrom MA, Freedman BI, Langefeld CD, Liu L, Hicks PJ, Bowden DW Association of adiponectin gene polymorphisms with type 2 diabetes in an African American population enriched for nephropathy. Diabetes 2009, 58(2):499-504.
39. Laudes M, Barroso I, Luan J, Soos MA, Yeo G, Meirhaeghe A, et al. Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 2004, 53(3):842-846.
40. Grarup N, Stender-Petersen KL, Andersson EA, Jorgensen T, Borch-Johnsen K, Sandbaek A, et al. Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects. Diabetes 2008, 57(4):1136-1142.
41. Oberkofler H, Linnemayr V, Weitgasser R, Klein K, Xie M, Iglseder B, et al. Complex haplotypes of the PGC-1alpha gene are associated with carbohydrate metabolism and type 2 diabetes. Diabetes 2004, 53(5):1385-1393.
42. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004, 47(12):2176-2184.
43. Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 2006, 49(3):501-505.
44. Lai CQ, Tucker KL, Parnell LD, Adiconis X, Garcia-Bailo B, Griffith J, et al. PPARGC1A variation associated with DNA damage, diabetes, and cardiovascular diseases: the Boston Puerto Rican Health Study. Diabetes 2008, 57(4):809-816.
45. Andersen G, Burgdorf KS, Sparso T, Borch-Johnsen K, Jorgensen T, Hansen T, et al. AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 white Danish subjects. Diabetes 2008, 57(5):1427-1432.
46. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 2005, 54(8):2477-2481.
47. Mussig K, Staiger H, Machicao F, Stancakova A, Kuusisto J, Laakso M, et al. Association of common genetic variation in the FOXO1 gene with beta-cell dysfunction, impaired glucose tolerance, and type 2 diabetes. J Clin Endocrinol Metab 2009, 94(4):1353-1360.
48. Bottcher Y, Tonjes A, Enigk B, Scholz GH, Bluher M, Stumvoll M, et al. A SNP haplotype of the forkhead transcription factor FOXO1A gene may have a protective effect against type 2 diabetes in German Caucasians. Diabetes Metab 2007, 33(4):277-283.
49. Friedrich B, Weyrich P, Stancakova A, Wang J, Kuusisto J, Laakso M, et al. Variance of the SGK1 gene is associated with insulin secretion in different European populations: results from the TUEF, EUGENE2, and METSIM studies. PLoS ONE 2008, 3(11):e3506.
50. Schwab M, Lupescu A, Mota M, Mota E, Frey A, Simon P, et al. Association of SGK1 gene polymorphisms with type 2 diabetes. Cell Physiol Biochem 2008, 21(1-3):151-160.
51. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, Sparso T, et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet 2010, 19(3):535-544.
52. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009, 361(12):1152-1163.
53. Bonnycastle LL, Wilier CJ, Conneely KN, Jackson AU, Burrill CP, Watanabe RM, et al. Common variants in maturity-onset diabetes of the young genes contribute to risk of type 2 diabetes in Finns. Diabetes 2006, 55(9):2534-2540.
54. Winckler W, Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007, 56(3):685-693.
55. Sandhu MS, Weedon MN, Fawcett KA, Wasson J, Debenham SL, Daly A, et al. Common variants in WFS1 confer risk of type 2 diabetes. Nat Genet 2007, 39(8):951-953.
56. Franks PW, Rolandsson O, Debenham SL, Fawcett KA, Payne F, Dina C, et al. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 2008, 51(3):458-463.
57. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006, 38(3):320-323.
58. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006, 355(3):241-250.
59. Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J Mol Med 2007, 85(7):777-782.
60. Elbein SC, Chu WS, Das SK, Yao-Borengasser A, Hasstedt SJ, Wang H, et al. Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 2007, 50(8):1621-1630.
61. Tabara Y, Osawa H, Kawamoto R, Onuma H, Shimizu I, Miki T, et al. Replication study of candidate genes associated with type 2 diabetes based on genome-wide screening. Diabetes 2009, 58(2):493-498.
62. Florez JC Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?. Diabetologia 2008, 51(7):1100-1101.
63. Omori S, Tanaka Y, Takahashi A, Hirose H, Kashiwagi A, Kaku K, et al. Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes 2008, 57(3):791-795.
64. Ng MC, Park KS, Oh B, Tam CH, Cho YM, Shin HD, et al. Implication of genetic variants nearTCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. Diabetes 2008, 57(8):2226-2233.
65. Grarup N, Rose CS, Andersson EA, Andersen G, Nielsen AL, Albrechtsen A, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 2007, 56(12):3105-3111.
66. Horikoshi M, Hara K, Ito C, Shojima N, Nagai R, Ueki K, et al. Variations in the HHEX gene are associated with increased risk of type 2 diabetes in the Japanese population. Diabetologia 2007, 50(12):2461-2466.
67. Lee YH, Kang ES, Kim SH, Han SJ, Kim CH, Kim HJ, et al. Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. J Hum Genet 2008, 53(11-12):991-998.
68. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316(5826):889-894.
69. Omori S, Tanaka Y, Horikoshi M, Takahashi A, Hara K, Hirose H, et al. Replication study for the association of new meta-analysis-derived risk loci with susceptibility to type 2 diabetes in 6,244 Japanese individuals. Diabetologia 2009, 52(8):1554-1560.
70. Boesgaard TW, Gjesing AP, Grarup N, Rutanen J, Jansson PA, Hribal ML, et al. Variant near ADAMTS9 known to associate with type 2 diabetes is related to insulin resistance in offspring of type 2 diabetes patients-EUGENE2 study. PLoS ONE 2009, 4(9):e7236.
71. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008, 40(9):1098-1102.
72. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008, 40(9):1092-1097.
73. Mussig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, Schafer SA, et al. Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 2009, 58(7):1715-1720.
74. Jonsson A, Isomaa B, Tuomi T, Taneera J, Salehi A, Nilsson P, et al. A variant in the KCNQ1 gene predicts future type 2 diabetes and mediates impaired insulin secretion. Diabetes 2009, 58(10):2409-2413.
75. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009, 41(1):77-81.
76. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009, 41(1):89-94.
77. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009, 41(1):82-88.
78. Mulder H, Nagorny CL, Lyssenko V, Groop L Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia 2009, 52(7):1240-1249.
79. Langenberg C, Pascoe L, Mari A, Tura A, Laakso M, Frayling TM, et al. Common genetic variation in the melatonin receptor 1B gene (MTNR1B) is associated with decreased early-phase insulin response. Diabetologia 2009, 52(8):1537-1542.
80. Staiger H, Machicao F, Schafer SA, Kirchhoff K, Kantartzis K, Guthoff M, et al. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS ONE 2008, 3(12):e3962.
81. Chambers JC, Zhang W, Zabaneh D, Sehmi J, Jain P, McCarthy MI, et al. Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians. Diabetes 2009, 58(11):2703-2708.
82. Ronn T, Wen J, Yang Z, Lu B, Du Y, Groop L, et al. A common variant in MTNR1B, encoding melatonin receptor 1B, is associated with type 2 diabetes and fasting plasma glucose in Han Chinese individuals. Diabetologia 2009, 52(5):830-833.
83. Frayling TM Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 2007, 8(9):657-662.
84. Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009, 41(10):1110-1115.
85. Reiling E, van't RE, Groenewoud MJ, Welschen LM, van Hove EC, Nijpels G, et al. Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk. Diabetologia 2009, 52(9):1866-1870.
86. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, Cavalcanti-Proenca C, et al. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 2008, 320(5879):1085-1088.
87. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, Orho-Melander M, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009, 18(21):4081-4088.
88. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010, 42(2):105-116.
89. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010, 42(2):142-148.
90. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20(3):284-287.
91. Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Volund A, et al. Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?. Diabetes 2003, 52(1):194-198.
92. Tonjes A, Scholz M, Loeffler M, Stumvoll M Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006, 29(11):2489-2497.
93. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, et al. The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 1999, 42(6):758-762.
94. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen GQ, et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000, 106(7):R69-R73.
95. Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. Diabetologia 2004, 47(5):782-793.
96. Saez ME, Gonzalez-Sanchez JL, Ramirez-Lorca R, Martinez-Larrad MT, Zabena C, Gonzalez A, et al. The CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population. PLoS ONE 2008, 3(8):e2953.
97. Abate N, Carulli L, Cabo-Chan A, Chandalia M, Snell PG, Grundy SM Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. J Clin Endocrinol Metab 2003, 88(12):5927-5934.
98. Kubaszek A, Pihlajamaki J, Karhapaa P, Vauhkonen I, Laakso M The K121Q polymorphism of the PC-1 gene is associated with insulin resistance but not with dyslipidemia. Diabetes Care 2003, 26(2):464-467.
99. Bacci S, De Cosmo S, Prudente S, Trischitta V ENPP1 gene, insulin resistance and related clinical outcomes. Curr Opin Clin Nutr Metab Care 2007, 10(4):403-409.
100. Stolerman ES, Manning AK, McAteer JB, Dupuis J, Fox CS, Cupples LA, et al. Haplotype structure of the ENPP1 Gene and Nominal Association of the K121Q missense single nucleotide polymorphism with glycemic traits in the Framingham Heart Study. Diabetes 2008, 57(7):1971-1977.
101. Mussig K, Heni M, Thamer C, Kantartzis K, Machicao F, Stefan N, et al. The ENPP1 K121Q polymorphism determines individual susceptibility to the insulin-sensitising effect of lifestyle intervention. Diabetologia 2010, 53(3):504-509.
102. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 2002, 51(1):37-41.
103. Buzzetti R, Petrone A, Zavarella S, Zampetti S, Spoletini M, Potenziani S, et al. The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects. Int J Obes (Lond) 2007, 31(3):424-428.
104. Fanelli M, Filippi E, Sentinelli F, Romeo S, Fallarino M, Buzzetti R, et al. The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers 2005, 21(4):175-180.
105. Stefan N, Thamer C, Staiger H, Machicao F, Machann J, Schick F, et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 2007, 92(5):1827-1833.
106. Dahlman I, Eriksson P, Kaaman M, Jiao H, Lindgren CM, Kere J, et al. alpha2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action. Diabetologia 2004, 47(11):1974-1979.
107. Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006, 55(9):2654-2659.
108. Brown AE, Yeaman SJ, Walker M Targeted suppression of calpain-10 expression impairs insulin-stimulated glucose uptake in cultured primary human skeletal muscle cells. Mol Genet Metab 2007, 91(4):318-324.
109. Paul DS, Harmon AW, Winston CP, Patel YM Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. Biochem J 2003, 376(Pt3):625-632.
110. Turner MD Coordinated control of both insulin secretion and insulin action through calpain-10-mediated regulation of exocytosis?. Mol Genet Metab 2007, 91(4):305-307.
111. Simonis-Bik AM, Nijpels G, van Haeften van Haeften TW, Houwing-Duistermaat JJ, Boomsma DI, Reiling E, et al. Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 2010, 59(1):293-301.
112. Grarup N, Andersen G, Krarup NT, Albrechtsen A, Schmitz O, Jorgensen T, et al. Association testing of novel type 2 diabetes risk alleles in the JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2 loci with insulin release, insulin sensitivity, and obesity in a population-based sample of 4,516 glucose-tolerant middle-aged Danes. Diabetes 2008, 57(9):2534-2540.
113. Stancakova A, Kuulasmaa T, Paananen J, Jackson AU, Bonnycastle LL, Collins FS, et al. Association of 18 confirmed susceptibility loci for type 2 diabetes with indices of insulin release, proinsulin conversion, and insulin sensitivity in 5,327 nondiabetic Finnish men. Diabetes 2009, 58(9):2129-2136.
114. Staiger H, Machicao F, Kantartzis K, Schafer SA, Kirchhoff K, Guthoff M, et al. Novel meta-analysis-derived type 2 diabetes risk loci do not determine prediabetic phenotypes. PLoS ONE 2008, 3(8):e3019.
115. Musso G, Gambino R, Pacini G, Pagano G, Durazzo M, Cassader M Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 2009, 49(2):426-435.
116. Tschritter O, Fritsche A, Stefan N, Haap M, Thamer C, Bachmann O, et al. Increased insulin clearance in peroxisome proliferator-activated receptor gamma2 Pro12Ala. Metabolism 2003, 52(6):778-783.
117. Maddux BA, Goldfine ID Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes 2000, 49(1):13-19.
118. Menzaghi C, Ercolino T, Salvemini L, Coco A, Kim SH, Fini G, et al. Multigenic control of serum adiponectin levels: evidence for a role of the APM1 gene and a locus on 14ql3. Physiol Genomics 2004, 19(2):170-174.
119. Qi L, Li T, Rimm E, Zhang C, Rifai N, Hunter D, et al. The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes 2005, 54(5):1607-1610.
120. Woo JG, Dolan LM, Deka R, Kaushal RD, Shen Y, Pal P, et al. Interactions between noncontiguous haplotypes in the adiponectin gene ACDC are associated with plasma adiponectin. Diabetes 2006, 55(2):523-529.
121. Trujillo ME, Scherer PE Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006, 27(7):762-778.
122. Kadowaki T, Yamauchi T Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(3):439-451.
123. Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K, et al. The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 2006, 52(10):1934-1942.
124. Kantartzis K, Staiger H, Machann J, Schick F, Claussen CD, Machicao F, et al. Adiponectin oligomers and ectopic fat in liver and skeletal muscle in humans. Obesity (Silver Spring) 2009, 17(2):390-392.
125. Lavoie JM, Gauthier MS Regulation of fat metabolism in the liver: link to non-alcoholic hepatic steatosis and impact of physical exercise. Cell Mol Life Sei 2006, 63(12):1393-1409.
126. Stefan N, Kantartzis K, Haring HU Causes and metabolic consequences of fatty liver. Endocr Rev 2008, 29(7):939-960.
127. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-lalpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34(3):267-273.
128. Kim JA, Wei Y, Sowers JR Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008, 102(4):401-414.
129. Kantartzis K, Thamer C, Peter A, Machann J, Schick F, Schraml C, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 2009, 58(9):1281-1288.
130. Hojlund K, Mogensen M, Sahlin K, Beck-Nielsen H Mitochondrial dysfunction in type 2 diabetes and obesity. Endocrinol Metab Clin North Am 2008, 37(3):713-731.
131. Mussig K, Staiger H, Machicao F, Machann J, Hennige AM, Schick F, et al. AHSG gene variation is not associated with regional body fat distribution - a magnetic resonance study. Exp Clin Endocrinol Diabetes 2009, 117(8):432-437.
132. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006, 29(4):853-857.
133. Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008, 57(10):2762-2767.
134. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemie stroke. Circulation 2008, 118(24):2555-2562.
135. Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008, 300(2):182-188.
136. Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, Fritsche A, et al. Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet 2009, 2(6):607-613.
137. Andreasen CH, Stender-Petersen KL, Mogensen MS, Torekov SS, Wegner L, Andersen G, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 2008, 57(1):10-95.
138. Haupt A, Thamer C, Machann J, Kirchhoff K, Stefan N, Tschritter O, et al. Impact of variation in the FTO gene on whole body fat distribution, ectopic fat, and weight loss. Obesity (Silver Spring) 2008, 16(8):1969-1972.
139. Dina C, Meyre D, Gallina S, Durand E, Korner A, Jacobson P, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 2007, 39(6):724-726.
140. Do R, Bailey SD, Desbiens K, Belisle A, Montpetit A, Bouchard C, et al. Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study. Diabetes 2008, 57(4):1147-1150.
141. Marvelle AF, Lange LA, Qin L, Adair LS, Mohlke KL Association of FTO with obesity-related traits in the Cebu Longitudinal Health and Nutrition Survey (CLHNS) Cohort. Diabetes 2008, 57(7):1987-1991.
142. Haupt A, Thamer C, Staiger H, Tschritter O, Kirchhoff K, Machicao F, et al. Variation in the FTO gene influences food intake but not energy expenditure. Exp Clin Endocrinol Diabetes 2009, 117(4):194-197.
143. Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 2007, 318(5855):1469-1472.
144. Wardle J, Carnell S, Haworth CM, Farooqi IS, O'Rahilly S, Plomin R Obesity associated genetic variation in FTO is associated with diminished satiety. J Clin Endocrinol Metab 2008, 93(9):3640-3643.
145. Cecil JE, Tavendale R, Watt P, Hetherington MM, Palmer CN An obesity-associated FTO gene variant and increased energy intake in children. N Engl J Med 2008, 359(24):2558-2566.
146. Tschritter O, Preissl H, Yokoyama Y, Machicao F, Haring HU, Fritsche A Variation in the FTO gene locus is associated with cerebrocortical insulin resistance in humans. Diabetologia 2007, 50(12):2602-2603.
147. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008, 40(6):768-775.
148. Wilier CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009, 41(1):25-34.
149. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadottir A, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009, 41(1):18-24.
150. Straub SG, Sharp GW Glucose-stimulated signaling pathways in biphasic insulin secretion. Diabetes Metab Res Rev 2002, 18(6):451-463.
151. Bratanova-Tochkova TK, Cheng H, Daniel S, Gunawardana S, Liu YJ, Mulvaney-Musa J, et al. Triggering and augmentation mechanisms, granule pools, and biphasic insulin secretion. Diabetes 2002, 51(Suppl 1):S83-S90.
152. Henquin JC Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 2009, 52(5):739-751.
153. Steiner DF, James DE Cellular and molecular biology of the beta cell. Diabetologia 1992, 35(Suppl 2):S41-S48.
154. Roder ME, Porte D, Schwartz RS, Kahn SE Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998, 83(2):604-608.
155. Kahn SE The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000, 108(Suppl 6a):2S-8S.
156. Ahren B Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005, 5(3):275-286.
157. Kahn SE, Hull RL, Utzschneider KM Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
158. Ren J, Jin P, Wang E, Liu E, Harlan DM, Li X, et al. Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. J Transi Med 2007, 5:1.
159. Hou JC, Min L, Pessin JE Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm 2009, 80:473-506.
160. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 1995, 96(5):2489-2495.
161. Remedi MS, Koster JC K(ATP) channelopathies in the pancreas. Pflugers Arch 2010, 460(2):307-320.
162. Fajans SS, Bell GI, Polonsky KS Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001, 345(13):971-980.
163. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006, 355(5):456.
164. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004, 53(10):2719-2722.
165. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006, 355(5):467.
166. Doyle ME, Egan JM Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007, 113(3):546-593.
167. Meier JJ The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2009, 23(4):433-441.
168. Villareal DT, Koster JC, Robertson H, Akrouh A, Miyake K, Bell GI, et al. Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes 2009, 58(8):1869-1878.
169. Stumvoll M, Fritsche A, Madaus A, Stefan N, Weisser M, Machicao F, et al. Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans. Diabetes 2001, 50(9):2161-2163.
170. Marshall C, Hitman GA, Partridge CJ, Clark A, Ma H, Shearer TR, et al. Evidence that an isoform of calpain-10 is a regulator of exocytosis in pancreatic beta-cells. Mol Endocrinol 2005, 19(1):213-224.
171. Turner MD, Fulcher FK, Jones CV, Smith BT, Aganna E, Partridge CJ, et al. Calpain facilitates actin reorganization during glucose-stimulated insulin secretion. Biochem Biophys Res Commun 2007, 352(3):650-655.
172. Schafer SA, Mussig K, Staiger H, Machicao F, Stefan N, Gallwitz B, et al. A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 2009, 52(6):1075-1082.
173. Sparso T, Andersen G, Albrechtsen A, Jorgensen T, Borch-Johnsen K, Sandbaek A, et al. Impact of polymorphisms in WFS1 on prediabetic phenotypes in a population-based sample of middle-aged people with normal and abnormal glucose regulation. Diabetologia 2008, 51(9):1646-1652.
174. Schafer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007, 50(12):2443-2450.
175. Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschritter O, Staiger H, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia 2008, 51(4):597-601.
176. Palmer ND, Lehtinen AB, Langefeld CD, Campbell JK, Haffner SM, Norris JM, et al. Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans. J Clin Endocrinol Metab 2008, 93(1):304-309.
177. Munoz J, Lok KH, Gower BA, Fernandez JR, Hunter GR, Lara-Castro C, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 2006, 55(12):3630-3634.
178. Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjogren M, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006, 55(10):2890-2895.
179. Boesgaard TW, Zilinskaite J, Vanttinen M, Laakso M, Jansson PA, Hammarstedt A, et al. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients - the EUGENE2 study. Diabetologia 2008, 51(5):816-820.
180. Palmer ND, Goodarzi MO, Langefeld CD, Ziegler J, Norris JM, Haffner SM, et al. Quantitative trait analysis of type 2 diabetes susceptibility loci identified from whole genome association studies in the Insulin Resistance Atherosclerosis Family Study. Diabetes 2008, 57(4):1093-1100.
181. Staiger H, Machicao F, Stefan N, Tschritter O, Thamer C, Kantartzis K, et al. Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS ONE 2007, 2(9):e832.
182. Staiger H, Stancakova A, Zilinskaite J, Vanttinen M, Hansen T, Marini MA, et al. A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 2008, 57(2):514-517.
183. Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 2008, 57(9):2503-2510.
184. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, et al. Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes 2007, 56(12):3101-3104.
185. Stancakova A, Pihlajamaki J, Kuusisto J, Stefan N, Fritsche A, Haring H, et al. Single-nucleotide polymorphism rs7754840 of CDKAL1 is associated with impaired insulin secretion in nondiabetic offspring of type 2 diabetic subjects and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 2008, 93(5):1924-1930.
186. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, et al. Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 2008, 51(9):1659-1663.
187. Tan JT, Nurbaya S, Gardner D, Ye S, Tai ES, Ng DP Genetic variation in KCNQ1 associates with fasting glucose and beta-cell function: a study of 3,734 subjects comprising three ethnicities living in Singapore. Diabetes 2009, 58(6):1445-1449.
188. Schwanstecher C, Meyer U, Schwanstecher M K(IR)6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic beta-cell ATP-sensitive K(+) channels. Diabetes 2002, 51(3):875-879.
189. Tschritter O, Stumvoll M, Machicao F, Holzwarth M, Weisser M, Maerker E, et al. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 2002, 51(9):2854-2860.
190. MacDonald PE, De Marinis YZ, Ramracheya R, Salehi A, Ma X, Johnson PR, et al. A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol 2007, 5(6):el43.
191. Brown MS, Goldstein JL Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 2008, 7(2):95-96.
192. Montminy M, Koo SH Diabetes: outfoxing insulin resistance?. Nature 2004, 432(7020):958-959.
193. Okamoto H, Hribal ML, Lin HV, Bennett WR, Ward A, Accili D Role of the forkhead protein FoxO1 in beta cell compensation to insulin resistance. J Clin Invest 2006, 116(3):775-782.
194. Buteau J, Spatz ML, Accili D Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. Diabetes 2006, 55(5):1190-1196.
195. Lang F, Gorlach A, Vallon V Targeting SGK1 in diabetes. Expert Opin Ther Targets 2009, 13(11):1303-1311.
196. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, et al. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005, 54(4):1090-1099.
197. Fritsche A, Stefan N, Hardt E, Haring H, Stumvoll M Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 2000, 43(7):852-858.
198. Bort R, Martinez-Barbera JP, Beddington RS, Zaret KS Hex homeobox gene-dependent tissue positioning is required for organogénesis of the ventral pancreas. Development 2004, 131(4):797-806.
199. Chimienti F, Devergnas S, Pattou F, Schuit F, Garcia-Cuenca R, Vandewalle B, et al. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion. J Cell Sei 2006, 119(Pt 20):4199-4206.
200. Picinato MC, Haber EP, Cipolla-Neto J, Curi R, Oliveira Carvalho CR, Carpinelli AR Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J Pineal Res 2002, 33(3):156-160.
201. Peschke E, Muhlbauer E, Musshoff U, Csernus VJ, Chankiewitz E, Peschke D Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002, 33(2):63-71.
202. Kemp DM, Ubeda M, Habener JF Identification and functional characterization of melatonin Mel la receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002, 191(2):157-166.
203. Peschke E Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008, 44(1):26-40.
204. Peschke E, Bach AG, Muhlbauer E Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res 2006, 40(2):184-191.
205. Ramracheya RD, Muller DS, Squires PE, Brereton H, Sugden D, Huang GC, et al. Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008, 44(3):273-279.
206. Verploegen S, Ulfman L, van Deutekom HW, van Aalst C, Honing H, Lammers JW, et al. Characterization of the role of CaMKI-like kinase (CKLiK) in human granulocyte function. Blood 2005, 106(3):1076-1083.
207. Rippe V, Drieschner N, Meiboom M, Murua EH, Bonk U, Belge G, et al. Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene 2003, 22(38):6111-6114.
208. Loos RJ, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, et al. TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population. Diabetes 2007, 56(7):1943-1947.
209. Stolerman ES, Manning AK, McAteer JB, Fox CS, Dupuis J, Meigs JB, et al. TCF7L2 variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. Diabetologia 2009, 52(4):614-620.
210. da Silva X, Loder MK, McDonald A, Tarasov AI, Carzaniga R, Kronenberger K, et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells. Diabetes 2009, 58(4):894-905.
211. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007, 117(8):2155-2163.
212. Pilgaard K, Jensen CB, Schou JH, Lyssenko V, Wegner L, Brons C, et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009, 52(7):1298-1307.
213. Villareal DT, Robertson H, Bell GI, Patterson BW, Tran H, Wice B, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010, 59(2):479-485.
214. Loder MK, da Silva X, McDonald A, Rutter GA TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta-cells. Biochem Soc Trans 2008, 36(Pt 3):357-359.
215. Yi F, Brubaker PL, Jin T TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005, 280(2):1457-1464.
216. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, et al. Wnt signaling regulates pancreatic beta cell proliferation. Proc Nati Acad Sei U S A 2007, 104(15):6247-6252.
217. Shu L, Sauter NS, Schulthess FT, Matveyenko AV, Oberholzer J, Maedler K Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets. Diabetes 2008, 57(3):645-653.
218. Shu L, Matveyenko AV, Kerr-Conte J, Cho JH, McIntosh CH, Maedler K Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009, 18(13):2388-2399.
219. Takeda K, Inoue H, Tanizawa Y, Matsuzaki Y, Oba J, Watanabe Y, et al. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 2001, 10(5):477-484.
220. Barrett TG, Bundey SE Wolfram (DIDMOAD) syndrome. J Med Genet 1997, 34(10):838-841.
221. Ishihara H, Takeda S, Tamura A, Takahashi R, Yamaguchi S, Takei D, et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004, 13(11):1159-1170.
222. Riggs AC, Bernal-Mizrachi E, Ohsugi M, Wasson J, Fatrai S, Welling C, et al. Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia 2005, 48(11):2313-2321.
223. Fonseca SG, Fukuma M, Lipson KL, Nguyen LX, Allen JR, Oka Y, et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem 2005, 280(47):39609-39615.
224. Towbin JA, Vatta M Molecular biology and the prolonged QT syndromes. Am J Med 2001, 110(5):385-398.
225. Vallon V, Grahammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, et al. KCNQl-dependent transport in renal and gastrointestinal epithelia. Proc Nati Acad Sei USA 2005, 102(49):17864-17869.
226. Fisher E, Boeing H, Fritsche A, Doering F, Joost HG, Schulze MB Whole-grain consumption and transcription factor-7-like 2 (TCF7L2) rs7903146: gene-diet interaction in modulating type 2 diabetes risk. Br J Nutr 2009, 101(4):478-481.
227. Qi L, Liang J Interactions between genetic factors that predict diabetes and dietary factors that ultimately impact on risk of diabetes. Curr Opin Lipidol 2010, 21(1):31-37.
228. Haupt A, Thamer C, Heni M, Ketterer C, Machann J, Schick F, et al. Gene Variants of TCF7L2 Influence Weight Loss and Body Composition During Lifestyle Intervention in a Population at Risk for Type 2 Diabetes. Diabetes 2010, 59(3):747-750.
229. Florez JC, Jablonski KA, McAteer J, Sandhu MS, Wareham NJ, Barroso I, et al. Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 2008, 51(3):451-457.
230. Brito EC, Lyssenko V, Renstrom F, Berglund G, Nilsson PM, Groop L, et al. Previously associated type 2 diabetes variants may interact with physical activity to modify the risk of impaired glucose regulation and type 2 diabetes: a study of 16,003 Swedish adults. Diabetes 2009, 58(6):1411-1418.
231. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56(8):2178-2182.
232. Janssens AC, Gwinn M, Valdez R, Narayan KM, Khoury MJ Predictive genetic testing for type 2 diabetes. BMJ 2006, 333(7567):509-510.
233. Weedon MN The importance of TCF7L2. Diabet Med 2007, 24(10):1062-1066.
234. Janssens AC, Pardo MC, Steyerberg EW, van Duijn CM Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am J Hum Genet 2004, 74(3):585-588.
235. Weedon MN, McCarthy MI, Hitman G, Walker M, Groves CJ, Zeggini E, et al. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 2006, 3(10):e374.
236. Cauchi S, Meyre D, Durand E, Proenca C, Marre M, Hadjadj S, et al. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS ONE 2008, 3(5):e2031.
237. Lango H, Palmer CN, Morris AD, Zeggini E, Hattersley AT, McCarthy MI, et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008, 57(11):3129-3135.
238. Schulze MB, Weikert C, Pischon T, Bergmann MM, Al Hasani H, Schleicher E, et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 2009, 32(11):2116-2119.
239. Sparso T, Grarup N, Andreasen C, Albrechtsen A, Holmkvist J, Andersen G, et al. Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia 2009, 52(7):1308-1314.
240. Yang Q, Khoury MJ, Friedman J, Little J, Flanders WD How many genes underlie the occurrence of common complex diseases in the population?. Int J Epidemiol 2005, 34(5):1129-1137.